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Background: In the European Union (EU) and United States (US), specific regulations have been released to
provide incentives to develop and sell orphan medicinal products.
We analysed the status of orphan drugs designated that not yet received a marketing authorisation or already
marketed for patients affected by rare diseases in the EU and US up to December 2015. For each drug, the
following data were extracted: designation date, active substance(s), orphan condition and indication, trade name,
approved therapeutic indication, approved ages, genetic nature of disease and if affects children.
Results: In the EU, 1264 Orphan Drug Designations have been granted and 133 medicinal products were approved
covering a total of 179 indications and 122 rare conditions. Among these, 79 were approved under Regulation (EC)
141/2000 (65 still listed in the Orphan Medicinal Products Register and 14 lost the orphan designation but still
authorised) and 23 were approved centrally by the European Agency before the Orphan Regulation entered into
force. On the other hand, in the US 3082 designations and 415 orphan products, covering a total of 521 indications
and 300 rare conditions, were granted. As a result, the mean of designations per year is 79 in the EU and 93.4 in
the US, while the mean of approved indications per year is 8.5 in the EU and 15.8 in the US.
No orphan product is marketed in the EU for bone and connective tissue, ophthalmic, poisoning/overdose, renal,
urinary and reproductive rare diseases. Among the marketed medicinal products, only 46.6% in the EU and 35.2% in
the US are approved for children.
If all the existing market approvals were merged, 362 additional therapeutic indications in the EU and 72 in the US
would be covered.
Conclusions: Our data show that notwithstanding the incentives issued, the number of medicines for rare diseases
is still limited, and this is more evident in certain therapeutic areas. However, by merging all the existing approvals,
patients would benefit of substantial advantages in both geographic areas. Efforts and cooperation between EU
and US seem the only way to speed up the development and marketing of drugs for rare diseases.
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Research and scientific progress in the rare disease field
is a challenging objective, since currently only few highly
specialised research centres deal with each specific con-
dition. Reasons accounting for this rely on the small
number of patients and the scarce economic return for
companies. Patients are geographically dispersed, few
patients can be recruited in clinical trials, and standard
Randomised Controlled Trials (RCTs) are of limited
feasibility. This makes longer and more difficult the
development process of drugs. In the European Union
(EU), United States (US) and elsewhere, specific regula-
tions have been released to provide incentives for com-
panies to develop medicines for diseases with a small
market, and the status of “orphan” drug has been
created [1, 2]. An “orphan drug” is for the diagnosis,
prevention or treatment of a disease so rare that the cost
of developing would not be covered without additional
incentives.
In details, in the EU a medicinal product is designated
as “orphan” if it is intended for the diagnosis, prevention
or treatment of a life-threatening or chronically/seriously
debilitating condition or affecting not more than five in
ten thousand persons in the EU or that without incen-
tives it is unlikely that the marketing of the product in
the Community would generate sufficient return to
justify the necessary investment. In addition, no satisfac-
tory method of diagnosis, prevention or treatment of the
condition in question shall have been authorised in
the EU or, if such method exists, the medicinal prod-
uct shall be of significant benefit to those affected by
that condition [1].
In the US is orphan any drug intended to treat a
disease or condition that affects less than 200.000
persons in the US (corresponding to a prevalence of 7.5
every 10.000 individuals) or affects more than 200.000
people and for which there is no reasonable expectationTable 1 Key incentives of the orphan legislation in the EU and US
Incentives In EU
Marketing exclusivity 10 years + 2 if paediatric
Clinical development costs –
Orphan designation free of charge
Support from agency during
the development process
free of charge protocol assistance
MAA 40% fee reduction; free of charge for SME
Fee reductions for SMEs 90% of fee reduction for post authorisatio
pre-authorisation inspections, post-authori
annual fees, during the first year after mar
Public funds (possible) incentives from EC (i.e. research
(possible) incentives in single Member Sta
development and MAthat the cost of developing and making it available, will
recovered from sales [2]. According to the EU and the
US regulations, for drugs designated as “orphan”, pharma-
ceutical companies are entitled to receive incentives
including grants, research support, fee waivers/reduction,
market exclusivity, and public diffusion of orphan
innovation [3], as shown in Table 1, in order to support
the availability on the market and to avoid the product is
abandoned, or the development is delayed [4].
Many “orphan” products would not have been de-
veloped outside the public funded orphan scheme, as
Hudson and coll. demonstrated for enzyme-replacement
therapies for the treatment of various mucopolysac-
charidoses [5]. On the other hand, as Westermark and
Linares pointed out, “patients with rare diseases still face
substantial problems and only a minority of their needs
have been addressed so far” [6]. In this context, the
rarity of pathologies and the geographical dispersion
represent hurdles for conducting adequate studies and
trials [7], especially because a great part of rare diseases
(nearly 50 to 75%) manifest during childhood [8, 9], and
paediatric trials have demonstrated to be more and more
difficult [10, 11].
Public registries and databases are key tools to in-
crease knowledge on rare diseases and facilitate research
[12, 13]. Many registries focused on rare conditions
exist, while databases on orphan drugs are few [14].
EuOrphan is a database focused on drugs aimed to diag-
nose, prevent or treat a rare disease. It was created by
Consorzio per Valutazioni Biologiche e Farmacologiche
in the framework of a funded European IT-Technology
project (eTen 510774 2003/C 118/19), as described by
Stakišaitis and coll [15]. Since 2008 it is voluntary
managed and regularly updated by Fondazione per la
Ricerca Farmacologica Gianni Benzi Onlus [16].
EuOrphan links administrative and scientific data on
designated and marketed drugs for rare diseases sourcedIn US
7 years
tax credits (up 50% of clinical
development costs)
free of charge
free of charge OOPD (Office of orphan
Products Development) assistance
s and for paediatric products fee reduction




grants) grants and contract for development
of orphan drugs
tes for research,
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and Drug Administration (FDA) [18] databases.
To the aim of this paper, we used data from EuOrphan
to depict the status of the orphan drugs designated that
not yet received a marketing authorisation or already
marketed for patients affected by rare diseases in the EU
in comparison with the orphan drugs marketed in the US.
We also analysed the advantages resulting for patients, if
the Orphan Drug Designations (ODDs) and approvals
would be merged between EU and US territories.
Methods
Sample
The sample of the analysis included:
Designations
Orphan Medicinal Products (OMPs) designated in the EU
in accordance with the Orphan Regulation (EC) 141/2000
[1], as listed in the Community Register of Orphan Medi-
cinal Products for human use; orphan drugs designated in
the US, as available from the register “FDA Orphan Drug
Designations and Approvals” since 1983 [18].
Medicinal products approved for a rare condition
To the aim of our research, we considered all the medi-
cines approved for a rare condition in the EU and listed
in the EC Pharmaceutical Community Register [17] that
includes: 1) OMPs approved for effect of Regulation
(EC) 141/2000 [1] by December, 31st 2015; 2) “orphan-
like drugs” [19, 20]; 3) non-orphan medicinal products
(non-OMPs) approved for a rare condition before the
Regulation [1] entered into force; 4) medicinal products
withdrawn by the EU OMPs Register but still marketed.
Orphan drugs approved by FDA, as listed in the register
“FDA Orphan Drug Designations and Approvals” [18].
The period of evaluation was from the entry into force




Active substance(s), designation date, sponsor, orphan
condition, the genetic nature of disease and if the condi-
tion affects children.
Medicinal products approved for a rare condition
Trade name, ATC (Anatomical Therapeutic Chemical
Classification System) code, approved therapeutic indica-
tion, approved ages, approval date, Marketing Authorisa-
tion Holder (MAH).
We considered that designations may be awarded to
multiple OMPs targeting the same rare disease, but
multiple designations may be awarded to one OMP
targeting different rare diseases, too, and a single OMPcould have more than one indication. In addition, more
than one sponsor may obtain a designation for the same
active substance and condition.
Rare condition
Rare conditions were derived by the orphan designa-
tions/approval opinions as published in the official EU
and FDA registries. In case of drugs which never re-
ceived an ODD, the rare condition has been identified in
Orphanet [21].
Data sources
European Medicines Agency (EMA) website (register of
designated Orphan Medicinal Products, list of European
Public Assessment Reports (EPARs), list of Class Waivers)
[22]; European Commission (EC) Community Register of
medicinal products [17]; FDA Orphan Drug Designations
and Approvals [18]; Orphanet [21], PubMed [23].
Classifications
For the purpose of the analysis, rare conditions were
classified according to the therapeutic area, their genetic
origin, and if affect the paediatric population.
Each rare condition was assigned to the following
disease areas, set from the existing classifications, such
as MedDRA, ICD-10 and Orphanet:
1. Bone and connective tissue diseases
2. Cardiovascular and respiratory diseases
3. Dermatological diseases
4. Endocrine diseases
5. Gastrointestinal and hepatobiliary diseases
6. Haematological diseases
7. Inborn errors of metabolism
8. Infectious and immune system diseases




13. Renal and genitourinary hereditary diseases
14. Others.
The information on the genetic nature of the disease
and if the condition affects the paediatric population
was searched on Orphanet [21]. Information on diseases
affecting adults only was also checked from the EMA list
of Class Waivers [22]. If not available, a literature search
was performed.
The age groups for which the drug is indicated were
classified in accordance with the ICH (International
Conference on Harmonization) Topic E11 Guideline
[24] and Paediatric Regulation [25]: PRETERM NEW
BORN INFANTS: up to 36 weeks gestation; TERM
NEWBORN INFANTS: 0–27 days; INFANTS AND
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ADOLESCENTS: 12–17 years (12–15 years in US);
ADULTS: over 18 years (over 16 in US).
Assumptions
In order to compare and merge the ODDs and drug
approvals granted in the EU and US, we assumed
that:
 The same designation is available both in the EU
and US if the active substance, the rare condition
and the MAH are the same between the two
territories or they are able to identify one or more
sub-contractors for drug distribution worldwide;
 The same medicinal product is available on both
the markets if the active substance, the rare
condition, the therapeutic indication and the age
covered by the indication are the same between
the two territories.
With the support of experts, we standardised the
names used for active substances and conditions, be-
cause we also found several differences between the
ODDs obtained by the same sponsor (also for the same
active substance and for the same condition).
Procedures for data quality, integrity and consistency
With the aim to guarantee data quality, integrity and
consistency of our database, different steps and respon-
sibilities were foreseen, as described below. A DataFig. 1 EuOrphan database update – process flowchartManager (DM) was in charge of extracting data from
EMA and FDA online databases every six months and
updating the EuOrphan database. Data extracted were
cleaned and filtered by in order to implement the
database.
When the EuOrphan database is correctly updated,
the Scientific Data Manager (SDM) was responsible for
implementing all the scientific information such as
disease characteristics, therapeutic area, genetic origin of
the disease and if affects children.
Finally, the Scientific Reviewer (SR) with the help of
experts when needed, performed a final check of the
information to be added to the database including stand-
ardisation of the names used for active substances,
conditions and indications.
Figure 1 shows in detail the flow of this process.
Statistical analysis
Descriptive statistics were performed for all the re-
corded variables. Trends across time of ODDs and
marketed products were analysed descriptively and in
terms of average figures over time, comparisons be-
tween EU and US were performed by means of
unpaired Student’s t test assuming the robustness of
the test for deviation from normality. Differences
between occurrences in the number of ODDs or mar-
keted drugs according to different stratification criteria
(e.g. genetic diseases, EU vs US) were tested by means
of chi-square test. The analyses were performed using
SPSS statistical software.
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Orphan designations
By December 31st 2015, 992 active substances from the
EU OMPs Register, corresponding to 1.264 ODDs, and
2.270 active substances, corresponding to 3.082 ODDs,
from the “FDA Orphan Drug Designations and Ap-
provals” register were entered into EuOrphan database.
The average number of designations per active substance
resulted to be slightly higher in the US compared to the
EU (1.36 vs 1.27).
Figure 2 shows the trends in the period 1983–2015 for
ODDs released per year by the EMA and the FDA. On
average, across the years 2000 and 2015 where data are
available for both the Agencies, a significantly lower
number of ODDs is observed for EMA compared to
FDA (79 vs 93.4, p = 0.009).
In the EU, the ODDs covered 370 rare diseases, of
which 319 affect children (86.2%) and 161 are genetic
(43.5%). In the US, the ODDs covered 800 rare diseases,
of which 672 affect children (84%) and 296 are genetic
(37%). Therefore, the most of rare diseases covered
by an ODD affect children both in the EU and US
(n.s. p = 0.34), while the percentage of genetic diseases
covered by an ODD is higher in the EU compared to
the US (p < 0.001).
Regarding the disease area, the largest number of
ODDs was detected in the oncologic area for both EU
and US, as shown in Fig. 3. Other ODDs have been
granted as supportive therapies to oncologic diseases (10
in the EU and 64 in the US) and classified in different
therapeutic areas (data not shown).
If all the existing EU and US designations were merged
between EU and US, a greater number of active
substances designated as “orphan” would be potentially
available to patients both from the EU and US.Fig. 2 Orphan designations in the EU and US released per yearAccordingly, we calculated the total number of ODDs
obtained by merging all the existing EU and US designa-
tions (Fig. 3, green column). Data shown in Fig. 3
demonstrate that the merge of the ODDs globally
granted in the EU and US resulted in 3552 ODDs. These
designations would cover 1015 rare diseases.
On average, the number of ODDs that reached the
market approval was globally low, but in the EU this
figure is significantly lower (P < 0.001) compared to the
US (8.5 versus 15.8).
Furthermore, the highest number of ODDs was spon-
sored by all commercial entities, big pharma or regula-
tory consultancy agencies both in the EU and US but
not the same firms are the mostly represented in the
two contexts.
Marketed drugs
In the EU, a total of 133 medicinal products, covering
179 indications for rare diseases, resulted on the
market. Among these approved indications, 139 were
approved by the European Medicines Agency under
the EU Regulation (EC)141/2000 [1] (116 of them are
still listed in the EU OMPs Register while 14 lost the
ODD but are still present on the market), 40 were
approved centrally by the European Medicines Agency
before the Orphan Regulation [1] entered into force
(6 of them were classified by the Agency as “orphan-
like drugs”).
In the US, 415 orphan drugs (covering 521 orphan
indications) were approved. The average number of indi-
cations per marketed medicinal product is slightly higher
in the EU compared to the US (1.34 vs 1.25).
Figure 4 shows the distribution of indications for rare
conditions in the EU and US per year. Similarly, to
ODDs, the mean number of marketed products per year
Fig. 3 Distribution of orphan designations per disease area
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marketed product per year in the US (8.5 vs 15.8, P <
0.001).
In addition, the percentage of genetic diseases covered
by an approved OMP is higher in the EU compared to
the US (47.5% vs 40.7%, p = 0.002): in the EU, 122 rare
conditions are covered by an authorised indication, of
which 58 are genetic; in the US, 300 rare conditions are
covered by an authorised indication, of which 122 are
genetic.
Distributing the approved indications by age, as stated
in the authorised product information leaflet (Fig. 5), we
demonstrated that 62 and 161 medicinal products,
covering a total of 77 and 186 paediatric indications,
were approved for the whole or part of the paediatric
population in the EU and US respectively. Noteworthy,
the official label was not available for seven ODs inFig. 4 Distribution of indications for rare conditions per yearthe FDA database. This means that 43% in the EU
and 35.7% in the US of indications were approved
for children.
We also calculated the number of indications ap-
proved only for adults even if the condition affects
children. This number resulted 64 in the EU and 242 in
the US. This means that 64/140 (45.7%) in the EU and
242/343 (70.5%) in the US (p < 0.0001) of the indications
for conditions affecting children are not approved for
the paediatric population.
For younger children, in the EU 33 and 32 out of
the total number of indications (18.4% and 17.9%)
were approved for preterm and term newborn infants
respectively; in the US, even if the total of the
indications approved for preterm and term newborn
infants were about twice higher than in the EU (73
and 72 respectively), the percentages are lower for
Fig. 5 Distribution of indications in the EU and US per age groups. Legend: label not available for 7 ODDs
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respectively).
In line with designations, the largest number of medi-
cinal products was detected in the oncologic area for
both agencies as shown in Fig. 6. However, in Europe no
drug was marketed for renal, urinary and reproductive
rare diseases and “poisoning/overdose”.
The MAHs with the highest number of desi-
gnations approved for the market are all commer-
cial entities, big pharma or regulatory consultancy
agencies.
As for the designations, considering the number of
therapeutic indications approved for the market, a
total of 348 rare diseases would have a marketed drug
in almost all the disease areas, as detailed in Fig. 6
(green column): 362 additional therapeutic indications
in the EU and 72 in the US would be covered.Fig. 6 Distribution of authorised indications for rare conditions per diseaseDiscussion
In line with previous publications [6, 26–29], the results
deriving from this study performed on EuOrphan data, re-
veal that, thanks to the incentives issued by the regulations
aimed at encouraging the development of OMPs, the
number of medicines for rare diseases greatly improved.
Actually, these regulations have clearly stimulated the
development of drugs for rare conditions, even those
previously untreatable, as demonstrated in the EU [30].
Up to 2015, in the EU and US ODDs result 1264 and
3082 respectively and the number of drugs approved for
the market 133 (10.5% out of the total of ODDs) in the
EU and 415 in the US (13.5% out of the total of ODDs).
This is in line with previous data claiming that the US
continues to have the most designations and the most
approvals [31], as well as with the reported “success rates”
(the proportion of orphan medicines that receivearea
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resulting similar in the EU and US [32].
This numerical disparity might be partially correlated
with the different date of entering into force of regula-
tions stimulating the development of orphan drugs for
rare diseases, since in the EU the orphan legislation [1]
came into force 20 years after the Orphan Drug Act in
the US [2].
Many publications dealing with the legislative frame-
works and differences among them are available in the
most relevant literature [31–33]. Firstly, we should take
into account that the legislations and policies encour-
aging the development of these medicines are to some
extent similar but not the same. The eligibilities for the
ODD slightly differ depending on the legislation and
policies adopted by each region [31]. For example, the
definition of “rare disease” based on prevalence is not
universal and depends on the legislation and policies
adopted by each region or country [34]: in the EU, a rare
disease is a condition affecting less than 5 individuals in
10.000 people, while in the US a rare disease is a
condition affecting less than 7.5 in 10.000 individuals.
In the EU, alternatively to the prevalence of the condi-
tion, the second criteria to designate an OMP considers
the lack of sufficient return generated from the marketing
of the medicinal product intended for a life-threatening,
seriously debilitating/serious and chronic conditions (even
when the prevalence is higher). Interestingly, in the EU
only one drug received the ODD on the basis of this sec-
ond criteria not referring to the low prevalence, namely
the “Recombinant modified vaccinia virus Ankara ex-
pressing tuberculosis antigen 85A” for the prevention of
tuberculosis disease in Bacille Calmette-Guérin (BCG)
vaccinated individuals [35]. Secondly, the differences be-
tween incentives set by the two legislations issued in the
US or in EU to stimulate the interest of pharmaceutical
companies in investing in the orphan drug sector (the Or-
phan Drug Act and European Regulation 141/2000) [1]
might be carefully considered. Grants, research design
support, fee waivers, tax incentives, orphan drug market
exclusivity, and public diffusion of orphan innovation are
main incentives for orphan R&D (Research and Develop-
ment) [4]. Both in the EU and US, the ODD and the
protocol assistance are free of charge. Protocol assistance
is a procedure through which regulatory authorities pro-
vide companies developing OMPs scientific advice on the
type of studies to be carried out to demonstrate the qual-
ity, efficacy, safety. In the EU, the protocol assistance or
scientific advice is given by the EMA Committee for
Medicinal Products for Human Use (CHMP) on the
recommendation of the Scientific Advice Working Party
(SAWP). In the US, it is given by the FDA Office of
Orphan Products Development (OOPD). Parallel scientific
advice/protocol assistance between EMA and FDA isavailable. In addition, the allocation of public funds and
fee reduction are available in both Agencies. On the other
hand, the granted marketing exclusivity is different (7 years
in the US and 10 years in the EU). What makes really the
difference is the economic support for the clinical devel-
opment costs, which is not set out by the orphan legisla-
tion in the EU, while in the US there are tax credits (up
50% of clinical development costs). However, EC research
programmes, such as the Sixth and Seventh Framework
Programmes and the ongoing Horizon 2020, have granted
and are granting funding also for OMPs development and
additional funds are requested to be provided by each
Member State.
Our analysis, which considered not only OMPs but
also the other medicinal products centrally approved in
the EU for a rare condition, highlights that the numer-
ical difference between EU and US is reduced if we
consider non-OMPs marketed in the EU before the
entry into force of the Regulation in the EU [1].
Approved OMPs are not the only medicines available on
the market. The title of “orphan” drug is gained if the
sponsor aims to receive incentives for the development
of an active substance intended for a rare disease
(according to the orphan legislation).
Our data confirm the most significant role of pharma-
ceutical companies/profit sponsors in the development
of orphan drugs.
If we look at specific therapeutic needs, we confirm
that the oncologic area is the most represented one,
because it includes the highest number of ODDs and the
highest number of approved medicinal products both in
the EU (377 and 32 respectively) and in the US (917 and
121 respectively), in line with previous data [14, 36]. A
significant number of ODDs has been developed for the
treatment of cystic fibrosis, amyotrophic lateral sclerosis
in both countries, as well as Duchenne muscular dys-
trophy and graft versus host disease in the EU.
Moreover, data from this study reveal that a great part
of genetic rare diseases has still an unmet therapeutic
need. Furthermore, all the 64 ODDs referring to the
following rare diseases did not receive the marketing
approval either in the EU (34 ODDs) or US (30 ODDs):
retinitis pigmentosa, corneal graft rejection, Leber's
congenital amaurosis, macular telangiectasia, focal seg-
mental glomerulosclerosis, low-flow priapism, nephrotic
syndrome, primary membranoproliferative glomerulo-
nephritis, uremic pruritus, autosomal dominant polycys-
tic kidney disease. We also demonstrated that in the EU
no drugs are marketed for poisoning/overdose, renal,
urinary and reproductive rare diseases.
With regards to paediatric medicines, our data demon-
strated that despite of the interest and the need for drugs
approved for children, about half of drugs approved in the
EU and US for a rare disease affecting children was not
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greater percentage of drugs with a paediatric indication
for rare conditions affecting children.
Furthermore, we found that few drugs were approved
for younger children, such as neonates (about 18% in the
EU and 14% in the US). So, in the US, even if the total
of the indications approved for preterm and term new-
born infants was about twice higher than in the EU, the
percentage out of the total number of approved indica-
tions is lower.
More in depth analyses are necessary on the paediatric
interest of each OMP to better evaluate the paediatric
needs for conditions affecting children.
So far, great efforts have been made by the European
Medicines Agency on the availability of drugs for rare
diseases, and continued efforts are still required from
the EU, its institutions and Member States [30]. As an
example, the Agency is going to shortly launch the
Priority Medicines (PRIME) scheme to push on the
development of medicines with unmet medical needs.
Finally, we tried to calculate the total coverage of
drugs marketed for rare diseases in the EU and US if the
efforts of the two agencies were joined and the designa-
tions and approvals were merged between the two terri-
tories. In this case, patients affected by rare diseases
would benefit of a greater number of drugs in all the
disease areas, both in the EU and US.
Similarly, Murakami and Narukawa demonstrated that
if the EU, US and Japan joined their ODDs, out of about
5000 designations, approximately 800 designations were
common among the USA, EU, and/or Japan [31]. How-
ever, as we experienced in performing this analysis,
several difficulties may arise in merging designations and
approvals, because terms and classifications are not
standardised and sponsors may differ between the two
regions as well as may differ from the manufacturer/
patent holder.
This joint effort would be made possible if regulatory
procedures were harmonised, and through efforts and
cooperation between the territories. The EMA and the
FDA started working together in 2008 and a Common
EMA/FDA Application Form for ODDs has been set up
for sponsors seeking orphan drug status in both the US
and EU. The FDA and the EMA have also agreed to
accept the submission of a single annual report from
sponsors of orphan products (drugs and biologics) desig-
nated for both the US and EU. The parallel submission
of orphan designation applications has been very suc-
cessful, with 62% of dossiers submitted in parallel to the
EMA and the FDA in 2012. To further encourage
applications for orphan designation to be submitted in
parallel by EMA and FDA, the two agencies also provide
parallel scientific advice to sponsors during the develop-
ment phase of their products [37].The expectations of both the agencies with respect to
the data are near about similar and sponsors can have a
common strategy at the very early stages of product
development [26]. Actually, this example of a common
approach seems the best way to go ahead.
Notwithstanding the giant steps made from the European
and American Agencies to harmonize their strategic
plans in the field of orphan drugs, we found difficulties
in collate information between the two Regulatory Bod-
ies (FDA and EMA), because the terminology and pro-
cesses are not completely harmonised. We even found
different terms of active substance and/or rare condi-
tion in ODDs obtained in the EU and US by the same
sponsor. Therefore, we were often unable to uniform
terms and to consider different two ODDs which were
practically the same.
Conclusions
Our results suggest that more efforts seem necessary to
increase the number of drugs obtaining the Marketing
Authorisation, which represents the first step for the
availability of medicines on the market, thus increasing
the coverage of patient needs. A more integrated
approach between Europe and United States in terms of
shared decisions, approvals, etc. would surely speed up
the development and then the marketing of drugs for
rare diseases. But we are aware that this is a challenging
goal.
Regarding the use of systematic collection and stored
of valid information on ODDs we consider that our
database demonstrated to be a useful tool to increase
knowledge on rare diseases and facilitate research. In
particular, EuOrphan has been recognised a valid source
of information in the context of an EU Commission
funded projects on rare diseases, such as InNerMeD-I-
NETWORK (Inherited NeuroMetabolic Diseases Infor-
mation Network, 2012 12 12, Second Health Programme)
focused on inherited neurometabolic diseases, and DEEP
(DEferiprone Evaluation in Paediatrics - 261483 - FP7-
HEALTH-F4-2010).
For the future, we aim to implement the database with
data on non-OMPs, namely the medicines approved for
rare diseases by the national Agencies and medicines
never receiving an ODD while approved by EMA after
the entry into force of Regulation (EC) 141/2000 for rare
diseases.
Currently, our major commitment is to make the
actual database easily accessible for researchers, com-
panies as well as for patients to search for information
and to disseminate all the available data on OMPs
approved and designated.
Abbreviations
ATC: Anatomical Therapeutic Chemical Classification System; BCG: Bacille
Calmette-Guérin; DM: Data Manager; EC: European Commission;
Giannuzzi et al. Orphanet Journal of Rare Diseases  (2017) 12:64 Page 10 of 11EMA: European Medicines Agency; EPAR: European Public Assessment
Report; EU: European Union; FDA: Food and Drug Administration;
ICH: International Conference on Harmonization; MAH: Marketing
Authorisation Holder; ODD: Orphan Drug Designation; OMP: Orphan
Medicinal Product; R&D: Research and Development; RCT: Randomised






Availability of data and material
The datasets generated and analysed during the current study are not
publicly available as the EuOrphan website is currently under construction
but are available from the corresponding author on reasonable request.
Authors’ contributions
VG designed the study, analysed data and drafted the manuscript. RC and
AL collected data and collaborated in drafting the manuscript. SO prepared
figures and one table. PB performed the statistical data analysis. DB
collaborated in preparing results and revised the manuscript. AC and FB
collaborated in the study design, analysing data and revised the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Fondazione per la Ricerca Farmacologica Gianni Benzi onlus, Via Abate
Eustasio, 30 – 70010 Valenzano, Italy. 2Consorzio per Valutazioni Biologiche e
Farmacologiche, Via L. Porta, 14 – 27100 Pavia, Italy. 3Istituti Clinici Scientifici
Maugeri SpA SB, Via Salvatore Maugeri, 4 – 27100 Pavia, Italy.
Received: 20 December 2016 Accepted: 21 March 2017
References
1. European Parliament and of the Council Regulation (EC) 141/2000
of 16 December 1999 on Orphan Medicinal Products. OJL 018/1,
22.01.2000.
2. Orphan Drugs Act of 1983. Public law 97-414. 97th Congress. Jan.4, 1983.
3. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visari J. Incentives
for orphan drug research and development in the United States. Orphanet
J Rare Dis. 2008;3:33.
4. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions
and misconceptions. Nat Rev Drug Discov. 2010;9:921–9.
5. Hudson I, Breckenridge A. The challenges of orphan drugs and orphan
diseases: real and imagined. Clin Pharmacol Ther. 2012;92(2):151–3.
6. Westermark K, Llinares J. Promoting the development of drugs against rare
diseases: what more should be done? Expert Rev Pharmacoecon Outcomes
Res. 2012;12(5):541–3.
7. International Rare Diseases Research Consortium. Policies & Guidelines,
Long version. 2013. Available from: http://www.irdirc.org/wpcontent/
uploads/2013/06/IRDiRC_policies_24MayApr2013.pdf. Accessed 16 Dec
2014.
8. World Health Organisation. Update on 2004 Background Paper 6.19 Rare
Diseases, Written by Van Weely S, Leufkens H.G.M. 2013. Available from:
http://www.who.int/medicines/areas/priority_medicines/en/.9. Eurordis. Rare Diseases: Understanding this public health priority. 2005.
[cited 2011 Apr 21]. Available from: http://www.eurordis.org/IMG/pdf/
princeps_document-EN.pdf.
10. Caldwell PHY, Murphy SB, Butow NP, Craig JC. Clinical trials in children.
Lancet. 2004;364(9436):803–11.
11. U.S. Department of Health and Human Services - FDA. Report: Complex Issues in
Developing Drugs and Biologic Products for Rare Diseases and Accelerating the
Development of Therapies for Pediatric Rare Diseases Including Strategic Plan:
Accelerating the Development of Therapies for Pediatric Rare Diseases. 2014.
Available from: http://www.fda.gov/downloads/RegulatoryInformation/
Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmend
mentstotheFDCAct/FDASIA/UCM404104.pdf. Accessed 8 Sept 2014.
12. Commission of the European Communities. Communication from the
Commission to the European Parliament, the Council, the European
Economic and Social Committee and the committee of the regions on Rare
Diseases: Europe’s Challenges. 2008. [COM(2008) 679 final].
13. Council Recommendation of 8 June 2009 on an action in the field of rare
diseases (2009/C 151/02). OJL 151, 3.07.2009.
14. Fitzgerald J, Bignami F. Orphan drug lists in Europe and US EURORDIS
archive. Updated 2012 May 21; cited 2009 Aug 19. Available from:
http://www.eurordis.org/content/orphan-druglists-europe-and-us.
Accessed 8 Sept 2014.
15. Stakisaitis D, Spokiene I, Juskevicius J, Valuckas KP, Baiardi P. Access to
information supporting availability of medicines for patients suffering from
rare diseases looking for possible treatments: the EuOrphan Service.
Medicina. 2007;43(6):441–6.
16. Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus. Available from:
www.benzifoundation.org.
17. European Commission Pharmaceuticals - Community Register of medicinal
products. Available from: http://ec.europa.eu/health/documents/
community-register/html/index_en.htm. Accessed 23 Mar 2016.
18. FDA – Food and Drug Administration. Available from: http://www.accessdata.
fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed 23 Mar 2016.
19. Ceci A, Felisi M, Baiardi P, Bonifazi F, Catapano M, Giaquinto C, Nicolosi A,
Sturkenboom M, Neubert A, Wong I. Medicines for children licensed by the
European Medicines Agency (EMEA): the balance after 10 years. Eur J Clin
Pharmacol. 2006;62(11):947–52.
20. European Medicine Agency. Inaugural Meeting of the Committee for
Orphan Medicinal Products (EMEA/COMP/5/00), 2000. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/12/
WC500016994.pdf. Accessed 11 Aug 2016.
21. Home - INSERM US14 (Institut national de la santé et de la recherche
médicale). Orphanet [Internet]. Orpha.net. 2016 [cited 8 September
2016]. Available from: http://www.orpha.net/consor/cgi-bin/index.php.
Accessed 11 Aug 2016.
22. Home - European Medicines Agency [Internet]. Ema.europa.eu. 2016 [cited
8 September 2016]. Available from: http://www.ema.europa.eu/ema/index.
jsp?curl=pages/home/Home_Page.jsp&mid =. Accessed 23 Mar 2016.
23. Home - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2016 [cited 13
December 2016]. Available from: https://www.ncbi.nlm.nih.gov/pubmed.
Accessed 20 July 2016.
24. International Conference on Harmonisation of technical requirements for
registration of pharmaceuticals for human use. ICH harmonised tripartite
guideline Clinical investigation of medicinal products in the pediatric
population E11. July 20th2000.
25. European Parliament and of the Council Regulation (EC) 1901/2006 of 12
December 2006 on medicinal products for paediatric use and amending
Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC
and Regulation (EC) No 726/2004.OJL 378/1, 27.12.2006.
26. Tiwari J. Navigating through orphan medicinal product regulations in EU and
US – Similarities and differences. Regul Toxicol Pharmacol. 2015;71(1):63–7.
27. Kwok AKoenigbauer F. Incentives to repurpose existing drugs for orphan
indications. ACS Med Chem Lett. 2015;6(8):828–30.
28. Uguen D, Lönngren T, Le Cam Y, Garner S, Voisin E, Incerti C, Dunoyer M,
Slaoui M. Accelerating development, registration and access to medicines
for rare diseases in the European Union through adaptive approaches:
features and perspectives. Orphanet J Rare Dis. 2014;9(1):20.
29. Eurordis Statement. Orphan drugs: Rising to the challenge to ensure a
better future for 30 million patients in Europe. Available from: http://www.
eurordis.org/sites/default/files/publications/Statement_Future_of_Orphan_
Drugs_14_October_09.pdf. Accessed 8 Sept 2014.
Giannuzzi et al. Orphanet Journal of Rare Diseases  (2017) 12:64 Page 11 of 1130. Committee for Orphan Medicinal Products and the European Medicines,
Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F,
Aarum S, Butlen-Ducuing F, et al. European regulation on orphan
medicinal products: 10 years of experience and future perspectives.
Nat Rev Drug Discov. 2011;10(5):341–9.
31. Murakami MNarukawa M. Matched analysis on orphan drug designations
and approvals: cross regional analysis in the United States, the European
Union, and Japan. Drug Discov Today. 2016;21(4):544–9.
32. Gammie T, Lu C, Babar Z. Access to orphan drugs: a comprehensive review
of legislations, regulations and policies in 35 countries. PLoS ONE. 2015;
10(10):e0140002.
33. Alqahtani S, Seoane-Vazquez E, Rodriguez-Monguio R, Eguale T. Priority
review drugs approved by the FDA and the EMA: time for international
regulatory harmonization of pharmaceuticals? Pharmacoepidemiol Drug Saf.
2015;24(7):709–15.
34. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today.
2013;18(3-4):163–72.
35. European Medicine Agency. Public summary of opinion on orphan
designation. Recombinant modified vaccinia virus Ankara expressing
tuberculosis antigen 85A for the prevention of tuberculosis disease in BCG
vaccinated individuals. EMA/COMP/317369/2005 Rev.3. March 13th 2006.
36. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research
stimulator or commercial opportunity? Health Policy. 2010;95(2-3):216–28.
37. Rodwell C., Aymé S., eds., “2014 Report on the State of the Art of Rare
Disease Activities in Europe”, July 2014. European Union, 2014.
Available from: http://www.eucerd.eu/upload/file/Reports/
2014ReportStateofArtRDActivitiesIV.pdf. Accessed 2 Mar 2017.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
